Pure Global
NCT03501550

Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL)

An Open-Label Phase 2a Study Evaluating the Safety and Efficacy of Combination Treatment With 2 Weeks of the Non-Nucleoside Inhibitor CDI 31244 Plus 6 Weeks of Sofosbuvir/Velpatasvir in Subjects With Chronic Hepatitis C Genotype 1 Infection
Cocrystal Pharma, Inc.·Phase 2·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Chronic Hepatitis C
Drug/Device/Intervention
CDI-31244
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Cocrystal Pharma, Inc.
Location
Baltimore, United States of America
Timeline & enrollment
Phase
Phase 2
Start date
Jun 26, 2018
End date
Jun 07, 2019
Enrollment
12 participants
Primary outcome

Number of Subjects With Treatment Emergent Adverse Events,Number of Participants With Sustained Virologic Response (SVR) 12 Weeks After Treatment

Summary

Open label phase 2a study of two week treatment with CDI-31244 and sofosbuvir and veltapasvir
 followed by four week treatment of sofosbuvir and velpatasvir in individuals with chronic
 hepatitis C (HCV) genotype 1 (GT1) infection

ICD-10 classifications
Chronic viral hepatitis CAcute hepatitis CChronic viral hepatitisOther chronic viral hepatitisChronic hepatitis, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT03501550
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT03501550 through Pure Global AI's free database. This Phase 2 trial is sponsored by Cocrystal Pharma, Inc. and is currently Completed. The study focuses on Chronic Hepatitis C. Target enrollment is 12 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.